High Density Lipoprotein (HDL) Functionality in Metabolic Syndrome

NCT00716300 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2009-02-18

No results posted yet for this study

Summary

The aim of the study is to examine the kinetic, anti-oxidant, anti-inflammatory and cellular cholesterol efflux properties of high-density lipoprotein (HDL) in subjects with the metabolic syndrome (MetS) and lean individuals.

Conditions

  • Metabolic Syndrome X

Sponsors & Collaborators

  • The University of Western Australia

    lead OTHER

Principal Investigators

  • Gerald F Watts, MBBS · The University of Western Australia

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2009-06-30
Completion
2009-12-31

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00716300 on ClinicalTrials.gov